Amanote Research
Register
Sign In
The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.
Journal of Acquired Immune Deficiency Syndromes
- United States
doi 10.1097/qai.0000000000001100
Full Text
Open PDF
Abstract
Available in
full text
Categories
Infectious Diseases
Pharmacology
Date
July 1, 2016
Authors
Unknown
Publisher
Ovid Technologies (Wolters Kluwer Health)
Related search
Tenofovir-Based Pre-Exposure Prophylaxis for HIV Prevention
Current Opinion in Infectious Diseases
Infectious Diseases
Microbiology
HIV Pre-Exposure Prophylaxis (PrEP): Effective but Controversial
Trends in Urology & Men's Health
Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients
ISRN Gastroenterology
O015 Establishment of a Monitoring Service for Men Who Have Sex With Men (MSM) Taking Generic Co-Formulated Tenofovir Disoproxil Fumarate (TDF)/emtricitabine (FTC) as Pre-Exposure Prophylaxis (PrEP) Against HIV Infection
Sexually Transmitted Infections
Dermatology
Infectious Diseases
Bone Mineral Density Changes Among HIV-Uninfected Young Adults in a Randomised Trial of Pre-Exposure Prophylaxis With Tenofovir-Emtricitabine or Placebo in Botswana
PLoS ONE
Multidisciplinary
Preparing for PrEP: Perceptions and Readiness of Canadian Physicians for the Implementation of HIV Pre-Exposure Prophylaxis
PLoS ONE
Multidisciplinary
Knowledge, Attitudes, and Experiences of HIV Pre-Exposure Prophylaxis (PrEP) Trial Participants in Botswana
World Journal of AIDS
HIV Pre-Exposure Prophylaxis
CMAJ
Medicine
Reduced Immune Activation During Tenofovir–Emtricitabine Therapy in HIV-Negative Individuals
Journal of Acquired Immune Deficiency Syndromes
Infectious Diseases
Pharmacology
